ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Drug Trials for Hearing Loss, Tinnitus Therapies Show Promise

by David Bronstein • June 8, 2015

  • Tweet
  • Email
Print-Friendly Version

Human trials of drug therapy for otology are few and far between. Whether it’s due to competing advances in amplification technology or the difficulty of determining a mechanism of action that could be consistently targeted by medications, pharmaceutical research has taken a back seat to hearing assistance devices.

You Might Also Like

  • Optimal Usage of Intratympanic Drug Therapy for Sudden Hearing Loss Unclear
  • Tinnitus Research Implicates Brain Structures in Hearing Disorder
  • New Drug May Help Prevent, Treat Tinnitus
  • Newly Identified Gene May Be Linked to Progressive Sensorineural Hearing Loss
Explore This Issue
June 2015

But that’s all beginning to change.

In just the last year, several phase 2 and 3 clinical trials of drug therapy for tinnitus and hearing loss have started adding patients. In some of the studies, interim results suggest significant advances. Even gene therapy, long talked about in otology circles but mostly a cancer-focused affair, has been tried in a handful of patients.

Thomas Meyer, PhD, chief executive officer of Auris Medical, a Basel, Switzerland-based company that has launched late-stage clinical trials of AM-101 and AM-111, two targeted intratympanic drugs for tinnitus and hearing loss, said the industry is poised for much-needed breakthroughs. “I believe we are now very close to seeing the arrival of what we call rational pharmacotherapy in inner ear disorders,” Dr. Meyer said.

Barbara Domayne-Hayman, DPhil, chief business officer of Autifony Therapeutics, a U.K.-based company that is actively recruiting U.S. patients for the CLARITY-1 study, the first trial of its kind to assess an oral medication for age-related hearing loss (ARHL), agreed that otologic drug research “is definitely headed in the right direction.”

Thomas Meyer, PhDI believe we are now very close to seeing the arrival of what we call rational pharmacotherapy in inner ear disorders.
—Thomas Meyer, PhD

The advances, she stressed, are sorely needed, given the limits of amplification technology. “Until now, hearing aids have been the primary focus of research and product development,” she said. “The problem with these devices is that they tend to amplify all sound; they don’t always do a very good job helping you interpret speech against a background of noise.” Indeed, she added, “that is why so many people who have been fitted with expensive hearing aids often leave them in the drawer at home; they don’t find them all that helpful in a noisy restaurant or work environment.”

That’s where the CLARITY-1 trial comes in. The phase 2a placebo-controlled, double-blind study’s goal is to assess changes in ARHL after four weeks of treatment in patients treated with the oral investigational drug AUT00063. The drug targets the Kv3 ion channel, “which is present on neurons throughout the auditory processing system,” Dr. Domayne-Hayman said. As patients age, Kv3 ion channel activity tends to decline (J Neurosci. 2004;24:1936-1940). That age-related decline is thought to contribute to auditory processing disorders, she added. “Our goal with AUT00063 is to enhance Kv3 ion channel firing in patients with age-related hearing loss, so that the brain is better able to process and discriminate sounds from background noise,” she said.

Pages: 1 2 3 4 | Single Page

Filed Under: Home Slider, Otology/Neurotology, Practice Focus, Special Report Tagged With: drugs, hearing loss, medication, tinnitusIssue: June 2015

You Might Also Like:

  • Optimal Usage of Intratympanic Drug Therapy for Sudden Hearing Loss Unclear
  • Tinnitus Research Implicates Brain Structures in Hearing Disorder
  • New Drug May Help Prevent, Treat Tinnitus
  • Newly Identified Gene May Be Linked to Progressive Sensorineural Hearing Loss

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • A Look at the Latest Research on Subglottic Stenosis
    • Weaning Patients Off of PPIs
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Did You Receive COVID-19 Relief? Here Are Reporting Considerations for 2021
    • Otolaryngology Experts Share Best Practices in Five Areas
    • How Climate Change May Be Affecting Sleep Patterns for Adults and Children
    • Laryngologists Discuss Tough Tracheostomy Choices During COVID-19 Era
    • Head and Neck Cancer: Experts Discuss How to Improve Surgery Quality and Value

Polls

Did you receive funding from the CARES Act or Paycheck Protection Program?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.